Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

Mauguen, Aa; Pignon, Jp; Burdett, Ss; Domerg, Cc; Fisher, Dd; Paulus, Rr; Mandrekar, Sj; Belani, Cp; Shepherd, Fa; Eisen, Tt; Pang, Hh; Collette, Ll; Sause, Wt; Dahlberg, Se; Crawford, Jj; Obrien, Mm; Schild, Se; Parmar, Mm; Tierney, Jf; Lepechoux, Cc; Michiels, Ss; Arriagada, Rr; Atagi, Ss; Auperin, Aa; Ball, Dd; Baumann, Mm; Behrendt, Kk; Belderbos, Jj; Bergman, Bb; Bishop, Jf; Bonner, Ja; Bozonnat, Mc; Choy, Hh; Clamon, Gg; Curran, Wj; Deruysscher, Dd; Dautzenberg, Bb; Dillman, Ro; Dische, Ss; Douillard, Jy; Dunant, Aa; Fournel, Pp; Furuse, Kk; Geyer, Ss; Grohen, Hj; Helle, Pa; Henryamar, Mm; Herndon, Je; Higgins, Jp; Huber, Rm; Imaizumi, Mm; Jeremic, Br; Johnson, Dh; Kato, Hh; Keller, Sm; Knuuttila, Aa; Koch, Rr; Koning, Cc; Legrand, Cc; Lechevalier, Tt; Mattson, Kk; Mineo, Tt; Mornex, Ff; Nankivell, Mm; Park, Jh; Rolland, Ee; Rosell, Rr; Sarıhan, SÜREYYA; Saunders, Mı; Scagliotti, Gv; Schaapveld, Mm; Seymour, Ll; Shibata, Tt; Souhami, Rl; Spiro, Sg; Stephens, Rj; Stewart, La; Strauss, Gm; Sylvester, Rr; Tada, Hh; Tanaka, Ff; Torri, Vv; Turrisi, At; Uitterhoeve, Aa; Ulm, Kk; Ulutin, Hakkı; Vanmeerbeck, Jj; Wada, Hh; Waller, Dd; Wang, Xf; Winter, Kk; Xu, Gc; Yamanaka, Tt; Zajusz, Aa

doi:10.1016/s1470-2045(13)70158-x

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

Atıf İçin Kopyala

Mauguen A., Pignon J., Burdett S., Domerg C., Fisher D., Paulus R., ...Daha Fazla

LANCET ONCOLOGY, cilt.14, ss.619-626, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 14
Basım Tarihi: 2013
Doi Numarası: 10.1016/s1470-2045(13)70158-x
Dergi Adı: LANCET ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.619-626
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background The gold standard endpoint in clinical trials of chemotherapy and radiotherapy for lung cancer is overall survival. Although reliable and simple to measure, this endpoint takes years to observe. Surrogate endpoints that would enable earlier assessments of treatment effects would be useful. We assessed the correlations between potential surrogate endpoints and overall survival at individual and trial levels.